Link to evidence summary Publication date: 07 September 2022 (Stakeholders may submit appeals to hta@doh.gov.ph until 22 September 2022 using the prescribe form found here: Topic Nomination ) Document Preview:
Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF
Document link: Evidence Summary (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via Topic Nomination.)
Preliminary Recommendation for the Inclusion of Potassium Citrate 1620 mg (15 mEq) Tablet in the PNF
Document link: HTAC Preliminary Recommendation of Potassium Citrate 15mEq Tablet (Proponents may submit appeals to hta@doh.gov.ph until 27 April 2022.) Document Preview:
Preliminary Recommendation for the Inclusion of Rituximab 1400 mg/11.7 mL Solution for Subcutaneous (SC) Injection for the Treatment of Non-Hodgkin’s Lymphoma
Document link: Evidence Summary on Subcutaneous Rituximab for the Treatment of Non-Hodgkin’s Lymphoma (Proponents may submit appeals to hta@doh.gov.ph until 18 March 2022.) Document Preview: